Free Trial

Indivior (INDV) Competitors

Indivior logo
GBX 987.74 +1.24 (+0.13%)
As of 03:22 AM Eastern

INDV vs. SOPH, ITH, HCM, GRI, SLS, ERGO, BMY, SLN, AMYT, and GPH

Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Sophos Group plc (SOPH.L) (SOPH), Ithaca Energy (ITH), HUTCHMED (HCM), Grainger (GRI), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Bloomsbury Publishing (BMY), Silence Therapeutics (SLN), Amryt Pharma (AMYT), and Global Ports (GPH). These companies are all part of the "pharmaceutical products" industry.

Indivior vs.

Indivior (LON:INDV) and Sophos Group plc (SOPH.L) (LON:SOPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Indivior currently has a consensus target price of GBX 1,650, indicating a potential upside of 67.05%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than Sophos Group plc (SOPH.L).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sophos Group plc (SOPH.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Sophos Group plc (SOPH.L) has a net margin of 0.00% compared to Indivior's net margin of -12.29%. Indivior's return on equity of 12.20% beat Sophos Group plc (SOPH.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior-12.29% 12.20% 2.37%
Sophos Group plc (SOPH.L) N/A N/A N/A

86.0% of Indivior shares are owned by institutional investors. 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.5%. Sophos Group plc (SOPH.L) pays an annual dividend of GBX 0.04 per share. Indivior pays out -1,875.0% of its earnings in the form of a dividend. Sophos Group plc (SOPH.L) pays out 2.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Indivior is clearly the better dividend stock, given its higher yield and lower payout ratio.

Indivior received 142 more outperform votes than Sophos Group plc (SOPH.L) when rated by MarketBeat users. Likewise, 80.43% of users gave Indivior an outperform vote while only 80.19% of users gave Sophos Group plc (SOPH.L) an outperform vote.

CompanyUnderperformOutperform
IndiviorOutperform Votes
559
80.43%
Underperform Votes
136
19.57%
Sophos Group plc (SOPH.L)Outperform Votes
417
80.19%
Underperform Votes
103
19.81%

Sophos Group plc (SOPH.L) has lower revenue, but higher earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Sophos Group plc (SOPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.15B1.10-£141M-£0.80-1,234.68
Sophos Group plc (SOPH.L)£726.90M0.00N/A£1.70N/A

In the previous week, Indivior's average media sentiment score of 0.00 equaled Sophos Group plc (SOPH.L)'saverage media sentiment score.

Company Overall Sentiment
Indivior Neutral
Sophos Group plc (SOPH.L) Neutral

Summary

Indivior beats Sophos Group plc (SOPH.L) on 12 of the 15 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INDV vs. The Competition

MetricIndiviorDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£1.27B£1.17B£5.21B£2.03B
Dividend Yield4.48%3.04%5.13%5.16%
P/E Ratio-1,234.68130.9089.421,927.13
Price / Sales1.102,866.551,240.04421,310.89
Price / Cash2.6810.2543.7529.19
Price / Book-10.973.225.313.07
Net Income-£141M£152.21M£122.54M£183.47M
7 Day Performance8.19%-0.04%1.42%3.08%
1 Month Performance8.01%3.29%2.51%3.53%
1 Year Performance-19.70%101.86%25.30%165.99%

Indivior Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDV
Indivior
1.7869 of 5 stars
GBX 987.74
+0.1%
GBX 1,650
+67.0%
-19.8%£1.27B£1.15B-1,234.681,000
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
ITH
Ithaca Energy
N/AGBX 134.20
+3.4%
N/A-1.9%£2.21B£1.91B1,118.33220
HCM
HUTCHMED
N/AGBX 242
-2.8%
N/A+5.0%£2.07B£610.81M-6,050.001,760
GRI
Grainger
3.0998 of 5 stars
GBX 214.50
flat
GBX 317.50
+48.0%
-14.8%£1.58B£270.30M8,183.33372Dividend Increase
SLS
Standard Life UK Smaller Companies Trust
N/AN/AN/AN/A£715.41M£222.48M3.3710
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386News Coverage
Negative News
BMY
Bloomsbury Publishing
2.9381 of 5 stars
GBX 602
-2.9%
GBX 825
+37.0%
+36.6%£490.27M£342.65M1,543.5934,300
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
GPH
Global Ports
N/AN/AN/AN/A£231.21M£193.58M30,000.0020Negative News

Related Companies and Tools


This page (LON:INDV) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners